4 results on '"Hélène Bouvaist"'
Number of results to display per page
Search Results
2. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
- Author
-
Olivier Sitbon, Gérald Simonneau, Pierre Clerson, Laurent Bertoletti, Grégoire Prévot, Virginie Gressin, Loïc Perchenet, François Picard, Hélène Bouvaist, Vincent Cottin, Emmanuel Bergot, and Matthieu Canuet
- Subjects
Pulmonary and Respiratory Medicine ,Endothelin Receptor Antagonists ,Pulmonary Arterial Hypertension ,Sulfonamides ,Download ,business.industry ,Conflict of interest ,Advertising ,Research Letters ,Tadalafil ,03 medical and health sciences ,0302 clinical medicine ,Pyrimidines ,030228 respiratory system ,Health care ,Medicine ,Humans ,Drug Therapy, Combination ,030212 general & internal medicine ,business ,Initial therapy ,Production team ,Agora - Abstract
Initial combination therapy plays a central role in managing pulmonary arterial hypertension (PAH) [1–4]. Patients with low- or intermediate-risk of 1-year mortality at diagnosis should be treated with initial combination therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase type-5 inhibitor (PDE5i) [2–4]. Benefits of initial therapy with the ERA ambrisentan and PDE5i tadalafil were demonstrated in AMBITION [1]; prospective evidence for other treatment combinations within these drug classes is needed., Initial combination therapy with macitentan and tadalafil is well tolerated and improves cardiopulmonary haemodynamics and functional capacity in newly diagnosed PAH patients https://bit.ly/3aWZagH
- Published
- 2020
3. 'Rehab for all!' Is it too early in pulmonary arterial hypertension?
- Author
-
Laurent Bertoletti, Arnaud Bourdin, Claire Dauphin, Irina Enache, Ségolène Turquier, Christophe Pison, David Montani, Marie-France Seronde, Hélène Bouvaist, Souad Bezzeghoud, Cécile Tromeur, Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Cardiologie, CHU Grenoble, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHU Clermont-Ferrand, Mitochondrie, stress oxydant et protection musculaire (MSP), Université de Strasbourg (UNISTRA), CHU Strasbourg, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( EA 3920) (PCVP / CARDIO), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique, Centre chirurgical Marie Lannelongue-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pneumologie, Hôpital du Kremlin Bicêtre, AP-HP, Paris, France., AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Infections Virales et Pathologie Comparée - UMR 754 (IVPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hospices Civils de Lyon (HCL), Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Université Grenoble Alpes (UGA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF), Université de Brest (UBO)-Université de Brest (UBO), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), and Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA)
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pulmonary Arterial Hypertension ,Rehabilitation ,business.industry ,Steering committee ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Hypertension, Pulmonary ,MEDLINE ,Evidence-based medicine ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Medicine ,Humans ,Familial primary pulmonary hypertension ,Familial Primary Pulmonary Hypertension ,030212 general & internal medicine ,business ,Intensive care medicine ,Exercise ,ComputingMilieux_MISCELLANEOUS - Abstract
Rehabilitation appears to be beneficial in PAH patients, but more research is needed before increasing the level of evidence for recommendations.http://bit.ly/33zutuZ
- Published
- 2019
- Full Text
- View/download PDF
4. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
- Author
-
Matthieu Canuet, David Montani, Xavier Jaïs, Olivier Sitbon, Anne Bergeron, Marc Humbert, Laurent Savale, Christophe Guignabert, Gérald Simonneau, Jason Weatherald, Andrei Seferian, Hélène Bouvaist, Pascal Magro, and Marie-Camille Chaumais
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Adolescent ,Hypertension, Pulmonary ,Dasatinib ,Hemodynamics ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,medicine ,Humans ,Registries ,Young adult ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Pulmonary hypertension ,Surgery ,BMPR2 ,Discontinuation ,medicine.anatomical_structure ,030228 respiratory system ,Vascular resistance ,Female ,Vascular Resistance ,France ,business ,medicine.drug ,Follow-Up Studies - Abstract
This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.21 incident, right heart catheterisation-confirmed cases of dasatinib-induced PAH were identified from the French Pulmonary Hypertension Registry. Clinical and haemodynamic variables were compared from baseline to last follow-up (median (range) 24 (1–81) months).Median age was 52 years and 15 patients were female (71%). 19 patients received dasatinib for chronic myelogenous leukaemia for a median (range) duration of 42 (8–74) months before PAH diagnosis. No bone morphogenic protein receptor-2 (BMPR2) mutations were found in the 10 patients tested. Dasatinib was uniformly discontinued and 11 patients received PAH medications. Four patients died during follow-up. New York Heart Association functional class improved from 76% in class III/IV to 90% in class I/II (pDasatinib-induced PAH frequently improves after discontinuation but persisted in over one-third of patients, therefore systematic follow-up is essential.
- Published
- 2017
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.